Results 1 to 10 of about 14,935 (222)
Leukapheresis and Hyperleukocytosis, Past and Future
International Journal of General Medicine, 2021 Dongdong Zhang,1 Yufan Zhu,2 Yanxia Jin,3 Natasha Mupeta Kaweme,3 Youhong Dong1 1Department of Oncology, Xiangyang No. 1 People’s Hospital, Hubei University of Medicine, Xiangyang, Hubei, 441000, People’s Republic of China; 2Orthopedics department ...
Dongdong Zhang +2 more
exaly +6 more sources
Turkish Journal of Internal Medicine, 2023 Background Hyperleukocytosis is a high-mortality emergency that must be diagnosed and treated promptly. The treatment options are low-dose cytosine arabinoside, hydroxyurea, steroids and leukapheresis.
Tuğcan Alp Kırkızlar +1 more
doaj +3 more sources
The Role of Therapeutic Leukapheresis in Hyperleukocytotic AML [PDF]
PLoS ONE, 2014 Hyperleukocytosis in AML with leukostasis is a serious life-threatening condition leading to a high early mortality which requires immediate cytoreductive therapy. Therapeutic leukapheresis is currently recommended by the American Society of Apheresis in
Friederike Pastore +2 more
exaly +2 more sources
Hematology, 2022 Objectives One of the treatment modalities that can be used for hyperleukocytosis is leukapheresis. However, the result of studies showing the benefit of early mortality through the use of leukapheresis versus no leukapheresis is still inconclusive ...
Ikhwan Rinaldi, Kevin Winston
exaly +2 more sources
Leukapheresis in Pediatric T-ALL with Extreme Hyperleukocytosis: A Case Highlighting the Importance of Early Recognition [PDF]
Journal of Investigative Medicine High Impact Case ReportsHyperleukocytosis (HL) in acute leukemia is associated with increased morbidity and mortality, mainly secondary to the effects of leukostasis. Many strategies for cytoreduction exist, however prompt initiation of chemotherapy is paramount.
Allison Guild DO +4 more
doaj +2 more sources
Cryopreserved leukapheresis enables scalable and distributed CAR-T manufacturing: a multi-platform comparative study [PDF]
Scientific ReportsCryopreserved leukapheresis is a scalable source for Chimeric antigen receptor T (CAR-T) manufacturing, yet it remains understudied (18.3% of 349 studies, 2010–2024).
Menglin Ren +7 more
doaj +2 more sources
Molecular Therapy - Methods and Clinical Development, 2021 The majority of CD19-directed CAR T cell products are manufactured using an autologous process. Although using a patient's leukapheresis reduces the risks of rejection, it introduces variability in starting material composition and the presence of cell ...
Carlotta Peticone, Daniel G Bracewell
exaly +3 more sources
GroβT rapidly and reliably mobilizes primitive hematopoietic stem and progenitor cells in nonhuman primates [PDF]
Molecular Therapy: Methods & Clinical DevelopmentAutologous hematopoietic stem cell (HSC) gene therapy has gone through remarkable advancements in recent years, especially for the treatment of sickle cell disease (SCD).
Andrea Repele +8 more
doaj +2 more sources
Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy
Scientific Reports, 2023 Optimized management of citrate-induced hypocalcemia is required to provide safe leukapheresis. We prospectively analyzed subjects who underwent leukapheresis for cytotherapy, and evaluated serum ionized (iCa) concentrations before, at the end of, and 1 ...
Tomoyasu Jo +8 more
doaj +1 more source
The factors influencing clinical outcomes after leukapheresis in acute leukaemia
Scientific Reports, 2021 Leukapheresis is used for the mechanical removal of leukaemic cells in hyperleukocytosis. However, the effectiveness of leukapheresis remains unclear due to selection and confounding factors in the cohorts.
Howon Lee +16 more
doaj +1 more source